Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis

References

• Sweeney SE, HarrisJr, ED, Firestein GS, Kelley W, Jeffery RC, Venables PJW. Clinical features of rheumatoid arthritis. In: Firestein GS, Kelley WN, editors. Kelley’s Textbook of Rheumatology. Vol. 38. Philadelphia, PA: Elsevier/Saunders; 2013;1109–1136. doi:10.1016/j.mpmed.2009.12.004
   Google Scholar
• Smolen JS. Treat-to-target: rationale and strategies. Clin Exp Rheumatol. 2012;30(4Suppl 73):S2–S6.
   Google Scholar
• Singh JA, Saag KG, Bridges SLJ, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68:1–25. doi:10.1002/acr.22783
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76:960–977. doi:10.1136/annrheumdis-2016-210715
   PubMed Web of Science ®Google Scholar
• Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ. 2006;15(12):1295–1310. doi:10.1002/hec.1148
   PubMed Web of Science ®Google Scholar
• Joensuu JT, Huoponen S, Aaltonen KJ, Konttinen YT, Nordström D, Blom M. The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: A systematic review. PLoS One. 2015;10:e0119683. doi:10.1371/journal.pone.0119683
   PubMed Web of Science ®Google Scholar
• Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus Placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):652–662. doi:10.1056/NEJMoa1608345
   PubMed Web of Science ®Google Scholar
• Vermeer M, Kuper HH, Hoekstra M, et al. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. Arthritis Rheum. 2011;63(10):2865–2872. doi:10.1002/art.30494
   PubMed Web of Science ®Google Scholar
• Steunebrink LMM, Vonkeman HE, Ten Klooster PM, Hoekstra M, van Riel PLCM, van de Laar MAFJ. Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM registry. Clin Rheumatol. 2016;35(3):609–615. doi:10.1007/s10067-016-3191-3
   PubMed Web of Science ®Google Scholar
• Prevoo ML, van ’T Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44–48. doi:10.1002/art.v38:1
   PubMed Web of Science ®Google Scholar
• Welsing PMJ, Severens JL, Hartman M, PLCM VR, Laan RFJM. Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands. Arthritis Care Res. 2004;51:964–973. doi:10.1002/art.20843
   Web of Science ®Google Scholar
• Welsing PMJ, Severens JL, Hartman M, van Gestel AM, PLCM VR, Laan RFJM. The initial validation of a Markov model for the economic evaluation of (new) treatments for rheumatoid arthritis. Pharmacoeconomics. 2006;24(10):1011–1020. doi:10.2165/00019053-200624100-00008
   Web of Science ®Google Scholar
• Schipper LG, Kievit W, den Broeder AA, et al. Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective. Rheumatology. 2011;50(7):1320–1330. doi:10.1093/rheumatology/ker084
   PubMed Web of Science ®Google Scholar
• Briggs A. Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value Heal. 2005;8:1–2. doi:10.1111/j.1524-4733.2005.08101.x
   PubMed Web of Science ®Google Scholar
• Hakkaart-van Roijen L, van der Linden N, Bouwmans CAM, Kanters T, Tan SS. Kostenhandleiding. Methodologie van Kostenonderzoek En Referentieprijzen Voor Economische Evaluaties in de Gezondheidszorg [Costing manual: Methodology of costing research and reference prices for economic evaluations in healthcare]. Zorginstituut Nederland. Geactualiseerde versie; 2015. Dutch.
   Google Scholar
• Rabin R, De Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337–343. doi:10.3109/07853890109002087
   PubMed Web of Science ®Google Scholar
• Lamers LM, Stalmeier PF, McDonnell J, Krabbe PF, van Busschbach JJ. Kwaliteit van leven meten in economische evaluaties: het Nederlands EQ-5D-tarief [Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff]. Ned Tijdschr Geneeskd. 2005;149(28):1574–1578. Dutch.
   PubMed Web of Science ®Google Scholar
• Dougados M, Van Der Heijde D, Chen YC, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2017;76:88–95. doi:10.1136/annrheumdis-2016-210094
   PubMed Web of Science ®Google Scholar
• van der Ploeg CPB, Pal S, Vroome ED, Bossche S. De Kosten van Ziekteverzuim Voor Werkgevers in Nederland [The Cost of Absenteeism for Employers in the Netherlands]. TNO; 2014. Available from: https://www.monitorarbeid.tno.nl/dynamics/modules/SPUB0102/view.php?pub_Id=100294&att_Id=4911. Accessed 20 March, 2020. Dutch.
   Google Scholar
• Tosh J, Stevenson M, Akehurst R. Health economic modelling of treatment sequences for rheumatoid arthritis: a systematic review. Curr Rheumatol Rep. 2014;16. doi:10.1007/s11926-014-0447-2.
   Web of Science ®Google Scholar
• Kievit W, Fransen J, Oerlemans AJM, et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis. 2007;66(11):1473–1478. doi:10.1136/ard.2007.072447
   PubMed Web of Science ®Google Scholar
• Zink A, Strangfeld A, Schneider M, et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum. 2006;54:3399–3407. doi:10.1002/art.22193
   PubMed Web of Science ®Google Scholar
• Dmfm VDH, Plcm VR, van Rijswijk MH. van de Putte LBA. Influence of prognostic features on the final outcome in rheumatoid arthritis: a review of the literature. Semin Arthritis Rheum. 1988. doi:10.1016/0049-0172(88)90013-3
   Web of Science ®Google Scholar
• Vermeer M, Kuper HH, Bernelot Moens HJ, et al. Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort. Arthritis Res Ther. 2012;14(6):R254. doi:10.1186/ar4099
   PubMed Web of Science ®Google Scholar